ASXL1 and chronic myelomonocytic leukemia: In a retrospective series of 174 patients with CMML, patients with TET2 mutations without ASXL1 mutation (~25% of patients) had the highest ORR (66% versus 47% for all other genotypes) and CR rate (32% versus 11% for all other genotypes) to HMA treatment.